相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children
Svea Stratmann et al.
LEUKEMIA (2023)
Present and Future Role of Immune Targets in Acute Myeloid Leukemia
Daniela Damiani et al.
CANCERS (2023)
Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia
Danielle C. Kirkey et al.
BLOOD ADVANCES (2023)
Synthetic receptors for logic gated T cell recognition and function
Sylvain Simon et al.
CURRENT OPINION IN IMMUNOLOGY (2022)
CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells
Yi Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2022)
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia
Mark B. Leick et al.
CANCER CELL (2022)
Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy
Pinar Ataca Atilla et al.
CYTOTHERAPY (2022)
A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia
Andy G. X. Zeng et al.
NATURE MEDICINE (2022)
Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia
Mayumi Sugita et al.
NATURE COMMUNICATIONS (2022)
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
Nawid Albinger et al.
BLOOD CANCER JOURNAL (2022)
Emerging CAR T Cell Strategies for the Treatment of AML
Paresh Vishwasrao et al.
CANCERS (2022)
Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges
Synat Kang et al.
FRONTIERS IN ONCOLOGY (2022)
Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia
Kening Li et al.
LEUKEMIA (2022)
Pediatric and young adult leukemia adoptive therapy (PLAT)-08: A phase 1 study of SC-DARIC33 in pediatric and young adults with relapsed or refractory CD33+ AML.
Todd Michael Cooper et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia
Han Dong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)
Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia
Rim Trad et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Integrated multiomic approach for identification of novel immunotherapeutic targets in AML
Thomas Koehnke et al.
BIOMARKER RESEARCH (2022)
Pathogenic Mechanisms in Acute Myeloid Leukemia
Sohini Chakraborty et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2022)
Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells
Mark Gurney et al.
CYTOTHERAPY (2022)
Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis
Hui Zhang et al.
LEUKEMIA (2022)
The Potential Role of 3D In Vitro Acute Myeloid Leukemia Culture Models in Understanding Drug Resistance in Leukemia Stem Cells
Basil Al-Kaabneh et al.
CANCERS (2022)
Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunity
Simone A. Minnie et al.
SCIENCE IMMUNOLOGY (2022)
Off-the-Shelf CD33 CAR-NK Cell Therapy for Relapse/Refractory AML: First-in-Human, Phase I Trial
Ruihao Huang et al.
BLOOD (2022)
Target Densities in Malignant and Normal Cells Determine CAR T Cell Efficacy and Off-Target Hematotoxicity
Sascha Haubner et al.
BLOOD (2022)
SINGLE-CELL TRANSCRIPTOMIC ATLAS-GUIDED DEVELOPMENT OF CHIMERIC ANTIGEN-RECEPTOR (CAR) T CELLS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
A. Gottschlich et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
NK cells and ILCs in tumor immunotherapy
Simona Sivori et al.
MOLECULAR ASPECTS OF MEDICINE (2021)
Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch
Walid Warda et al.
CANCER GENE THERAPY (2021)
Cytokine-Induced Memory-like NK Cells Have a Distinct Single Cell Transcriptional Profile and Persist for Months in Adult and Pediatric Leukemia Patients after Adoptive Transfer
Jennifer A. Foltz et al.
BLOOD (2021)
A modular and controllable T cell therapy platform for acute myeloid leukemia
Mohamed-Reda Benmebarek et al.
LEUKEMIA (2021)
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
Eryn Blass et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML
Martin Wermke et al.
BLOOD (2021)
TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential
Mansour Poorebrahim et al.
CANCER GENE THERAPY (2021)
Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia
Antonio Pierini et al.
BLOOD ADVANCES (2021)
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity
Tim Sauer et al.
BLOOD (2021)
CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma
Sabrina Prommersberger et al.
GENE THERAPY (2021)
Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes
Gregory Ehx et al.
IMMUNITY (2021)
Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities
Ilias Christodoulou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia
Francesco Paolo Tambaro et al.
LEUKEMIA (2021)
Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models
Dina Schneider et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia
Hardikkumar Jetani et al.
BLOOD (2021)
The efficacy and safety of anti-CLL1 based CAR-T cells in children with relapsed or refractory acute myeloid leukemia: A multicenter interim analysis.
Hui Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Qingya Cui et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
Faroogh Marofi et al.
STEM CELL RESEARCH & THERAPY (2021)
A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy
Emily J. Pomeroy et al.
MOLECULAR THERAPY (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
Rebecca Epperly et al.
FRONTIERS IN ONCOLOGY (2020)
Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia
Simon Loff et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers
Sareetha Kailayangiri et al.
CANCERS (2020)
The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies
Tobias Bald et al.
NATURE IMMUNOLOGY (2020)
Multidimensional study of the heterogeneity of leukemia cells in t(8;21) acute myelogenous leukemia identifies the subtype with poor outcome
Lu Jiang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody
Martina Geiger et al.
NATURE COMMUNICATIONS (2020)
CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia
Melinda A. Biernacki et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Sleeping Beauty engineered CAR T cells achieve antileukemic activity without severe toxicities
Chiara F. Magnani et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells
Liangshun You et al.
FRONTIERS IN IMMUNOLOGY (2020)
HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study
Peter van Balen et al.
FRONTIERS IN IMMUNOLOGY (2020)
Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia
Pinar Ataca Atilla et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDS
Anna Stengel et al.
BLOOD ADVANCES (2020)
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy
Kevin A. Hay et al.
BLOOD (2019)
Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity
Peter van Galen et al.
CELL (2019)
Targeting RIPK1 for the treatment of human diseases
Alexei Degterev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
Susanne Hofmann et al.
JOURNAL OF CLINICAL MEDICINE (2019)
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant
Aude G. Chapuis et al.
NATURE MEDICINE (2019)
Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)
Caitlin L. Costello et al.
BLOOD (2019)
A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation
Emma C. Morris et al.
BLOOD (2019)
GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy
Lucia Fernandez et al.
FRONTIERS IN IMMUNOLOGY (2019)
Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts
Carter M. Suryadevara et al.
CLINICAL CANCER RESEARCH (2019)
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia
Dyantha van der Lee et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia
Diogo Gomes-Silva et al.
MOLECULAR THERAPY (2019)
Acute myeloid leukemia and NK cells: two warriors confront each other
Aroa Baragano Raneros et al.
ONCOIMMUNOLOGY (2019)
Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG plus AML
Sun Yao et al.
FRONTIERS IN ONCOLOGY (2019)
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
Miriam Y. Kim et al.
CELL (2018)
Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia
Jessica C. Petrov et al.
LEUKEMIA (2018)
Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells
Wei Xiong et al.
MOLECULAR THERAPY (2018)
Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.
Tapan M. Kadia et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system
Michael Hudecek et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2018)
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
Regina Jitschin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial
Fang Liu et al.
BLOOD (2018)
Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells
Dimitris Karamitros et al.
NATURE IMMUNOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients
J. Pan et al.
LEUKEMIA (2017)
Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia
Silvia Arcangeli et al.
MOLECULAR THERAPY (2017)
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1
Haruko Tashiro et al.
MOLECULAR THERAPY (2017)
Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS
Isao Tawara et al.
BLOOD (2017)
Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML
Fabiana Perna et al.
CANCER CELL (2017)
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia
Sarah K. Tasian et al.
BLOOD (2017)
Therapeutic targeting of acute myeloid leukemia stem cells
Daniel A. Pollyea et al.
BLOOD (2017)
Biology and relevance of human acute myeloid leukemia stem cells
Daniel Thomas et al.
BLOOD (2017)
Harnessing the immune system in acute myeloid leukaemia
Rebecca Austin et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Chimeric antigen receptors: driving immunology towards synthetic biology
Michel Sadelain
CURRENT OPINION IN IMMUNOLOGY (2016)
Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution
M. Ryan Corces et al.
NATURE GENETICS (2016)
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia
Sheng Li et al.
NATURE MEDICINE (2016)
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Matthew S. Davids et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Eric Tran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
Rizwan Romee et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors
Daniel T. Harris et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
M. Cartellieri et al.
BLOOD CANCER JOURNAL (2016)
Mutations in AML: prognostic and therapeutic implications
Courtney D. DiNardo et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Allogeneic Tcra/β Deficient CAR T-Cells Targeting CD123 Prolong Overall Survival of AML Patient-Derived Xenografts
Monica L. Guzman et al.
BLOOD (2016)
Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)
Naval Daver et al.
BLOOD (2016)
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
Soranobu Ninomiya et al.
BLOOD (2015)
Targeting cancer-specific mutations by T cell receptor gene therapy
Thomas Blankenstein et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes
Cyrille J. Cohen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
S. S. Kenderian et al.
LEUKEMIA (2015)
Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
Quan-shun Wang et al.
MOLECULAR THERAPY (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
R. Coleman Lindsley et al.
BLOOD (2015)
The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity
Jacques C. Mbongue et al.
VACCINES (2015)
The past and future of CD33 as therapeutic target in acute myeloid leukemia
George S. Laszlo et al.
BLOOD REVIEWS (2014)
Evolution of the Cancer Stem Cell Model
Antonija Kreso et al.
CELL STEM CELL (2014)
Acute Myelogenous Leukemia-Induced Sympathetic Neuropathy Promotes Malignancy in an Altered Hematopoietic Stem Cell Niche
Maher Hanoun et al.
CELL STEM CELL (2014)
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Pierre G. Coulie et al.
NATURE REVIEWS CANCER (2014)
Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia
Mareike Rickmann et al.
ANNALS OF HEMATOLOGY (2013)
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
Isabel Ben-Batalla et al.
BLOOD (2013)
Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment
Francis Mussai et al.
BLOOD (2013)
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma
Monica Casucci et al.
BLOOD (2013)
Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
David S. Ritchie et al.
MOLECULAR THERAPY (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Julie Schanz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia
Max Jan et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Differential niche and Wnt requirements during acute myeloid leukemia progression
Steven W. Lane et al.
BLOOD (2011)
PRAME-Specific Allo-HLA-Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer
Avital L. Amir et al.
CLINICAL CANCER RESEARCH (2011)
Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies
Marleen M. van Loenen et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Proteomic cell surface phenotyping of differentiating acute myeloid leukemia cells
Andreas Hofmann et al.
BLOOD (2010)
Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia
Qing Zhou et al.
BLOOD (2009)
A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells
Claudine Graf et al.
BLOOD (2007)
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability
Cyrille J. Cohen et al.
CANCER RESEARCH (2006)
An inducible caspase 9 safety switch for T-cell therapy
KC Straathof et al.
BLOOD (2005)
Leukaemia stem cells and the evolution of cancer-stem-cell research
BJP Huntly et al.
NATURE REVIEWS CANCER (2005)
Exploiting T cell receptor genes for cancer immunotherapy
S Xue et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
C-type lectin-like molecule-1: A novel myeloid cell surface marker associated with acute myeloid leukemia
ABH Bakker et al.
CANCER RESEARCH (2004)
Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia
WAE Marijt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias
S Dias et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells
CT Jordan et al.
LEUKEMIA (2000)
Expression of CD44 variant exons in acute myeloid leukemia is more common and more complex than that observed in normal blood, bone marrow or CD34+ cells
LJ Bendall et al.
LEUKEMIA (2000)